Views: 1,312 | Downloads:
17
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Effects of Paclitaxel and Carboplatin on Quality of Life and Survival in Patients with Advanced Non-Small-Cell Lung Cancer
Ratanatharathorn V 
,
Sirachainan E ,
Jirajarus M
,
Sirachainan E ,
Jirajarus M The purpose of this phase II study was to detennine the effects of paclitaxel plus car-
boplatin administered by short duration on response rate, toxicity, and quality of life (QOL) in
patients with non-small cell lung cancer (NSCLC). Twenty-seven patients were enrolled in this
study. The objective response rate was 48.2 per cent, grade 3 or 4 granulocytopenia and throm-
bocytopenia were observed in 22 per cent and 1.6 per cent, respectively. QOL was assessed in
nineteen patients who completed six cycles of chemotherapy. Quality of Life Index (QLI) after
six cycles of treatment showed no significant change from the baseline QOL. Compliance with
the QOL protocol in this study diminished with the course of chemotherapy which is comparable
to the literature figure. Thus, withholding current effective chemotherapy in patients with NSCLC
with good performance status is no longer justified.
Key word : Non-Small-Cell Lung Cancer, Chemotherapy, Quality of Life, Paclitaxel. Carboplatin
boplatin administered by short duration on response rate, toxicity, and quality of life (QOL) in
patients with non-small cell lung cancer (NSCLC). Twenty-seven patients were enrolled in this
study. The objective response rate was 48.2 per cent, grade 3 or 4 granulocytopenia and throm-
bocytopenia were observed in 22 per cent and 1.6 per cent, respectively. QOL was assessed in
nineteen patients who completed six cycles of chemotherapy. Quality of Life Index (QLI) after
six cycles of treatment showed no significant change from the baseline QOL. Compliance with
the QOL protocol in this study diminished with the course of chemotherapy which is comparable
to the literature figure. Thus, withholding current effective chemotherapy in patients with NSCLC
with good performance status is no longer justified.
Key word : Non-Small-Cell Lung Cancer, Chemotherapy, Quality of Life, Paclitaxel. Carboplatin
Download:
PDF